Eisai Epilepsy Drug Rufinamide Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking indications to treat Lennox-Gastaut syndrome and partial-onset seizures for the new molecular entity.
You may also be interested in...
Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures
Drug is "approvable" for Lennox-Gastaut syndrome, partial onset seizures since 2006.
Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures
Drug is "approvable" for Lennox-Gastaut syndrome, partial onset seizures since 2006.
Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.